Correlative Studies with Specimens from Multi-Site Trials (R21)

The summary for the Correlative Studies with Specimens from Multi-Site Trials (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Correlative Studies with Specimens from Multi-Site Trials (R21): This funding opportunity is intended to support correlative studies by using tumor specimens collected during multi-institutional clinical trials. The Cancer Therapy Evaluation Program (CTEP), the Cancer Diagnosis Program (CDP), and the Cancer Biomarkers Research Group (CBRG) from the NCI will cooperatively sponsor this funding opportunity with the following objectives to: (1) provide investigators with support for correlative studies using trial-related tumor specimens to compare genetic variations and molecular changes from the cell nucleus, the cytosol, and the cell surface and extracellular matrix to tumorigenesis and progression, drug resistance, therapeutic effectiveness of interventions, and patients' clinical outcomes; (2) decipher mechanisms and to evaluate new cancer interventions by utilizing these tumor tissue resources and accumulated clinical trial results for better cancer risk assessment, early detection, and prediction of response to various cancer therapies and prevention strategies; and (3) promote translational research and foster collaborations between basic researchers and clinical investigators from academia, private industry, and non-profit organizations to ensure that new findings will be rapidly translated into clinical practice. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. -This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-05-062, that solicits applications under the NIH Research Project Grant (R01) mechanism. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations include: for-profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of State Tribal governments; units of local governments; units of local Tribal governments; eligible institutions of the Federal government; domestic institutions; foreign institutions; and faith-based or community-based organizations. -Eligible Project Directors/Principal Investigators (PDs/PIs) include any individuals from the applicant institutions who have the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct.
Federal Grant Title: Correlative Studies with Specimens from Multi-Site Trials (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-06-296
Type of Funding: Grant
CFDA Numbers: 93.39393.394
CFDA Descriptions: Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research
Current Application Deadline: No deadline provided
Original Application Deadline: May 07, 2008 Multiple Receipt Dates - See Link to
Posted Date: Mar 29, 2006
Creation Date: Apr 04, 2008
Archive Date: May 04, 2008
Total Program Funding:
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: 93.395 -- Cancer Treatment Research
Applicants Eligible for this Grant
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Independent school districts City or township governments County governments For profit organizations other than small businesses State governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Special district governments Public housing authorities/Indian housing authorities Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply. Faith-based or community-based organizations
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster